Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized comparison of reduced COVID-19 mRNA vaccination regimens in paediatric subjects
2021-005043-71Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of RH109 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary: Neutralizing antibody titers against wild-type SARS-CoV-2 at day 28. Started Oct 2021; status: active.
02
Drugs
RH109
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-005043-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005043-71.